Advances in biotechnology, a greater understanding of the immunopathogenesis of rheumatoid arthritis (RA) and a desire for more effective therapeutics have led to the development of a class of ...

SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today ...

Rheumatoid arthritis (RA) remains a significant global health challenge, particularly in the context of biological therapy where the immune system’s response to therapeutic agents can critically ...

Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo-controlled ...

Rheumatoid arthritis is a painful, progressive joint disease characterized by particularly acute flare-ups. Biologics, used to treat autoimmune diseases such as rheumatoid arthritis, target symptom ...

Early escalation to biologic therapies after failure of treat-to-target with methotrexate in patients with rheumatoid arthritis (RA) does not significantly reduce the risk for the development of ...

Rheumatoid arthritis (RA) is an inflammatory arthritis characterized by chronic joint inflammation, cartilage degradation, and bone erosion. ELK3 is a transcriptional repressor that can affect cell ...

SetPoint Medical to Present Data at ACR Convergence 2025 Demonstrating Sustained Efficacy and Safety for the SetPoint System to Treat Rheumatoid Arthritis Four presentations highlight 12-month ...

Original Medicare covers most medically necessary treatments for rheumatoid arthritis (RA), including biologics like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra), and ...

psoriasis RA biologic treatment The use of biologic agents in treatment of patients rheumatoid arthritis or psoriasis is associated with a significant risk of heptatis B flares. “The emergence of ...